Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.

ABSTRACT:

Background & aims

Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Multiple mechanisms may be important including weight loss, improved glycaemic control and putative direct tissue-specific actions. Following cessation of GLP1-RA therapy, weight regain is common. To dissect the mechanisms underpinning their benefits, we conducted a prospective, randomised, experimental medicine study in people with MASLD, comparing GLP-1RA treatment (liraglutide) to matched lifestyle-induced weight loss and assessed the impact of treatment withdrawal.

Methods

Twenty-nine participants with MASLD, without type 2 diabetes underwent metabolic phenotyping including measurement

SUBMITTER: Moolla A 

PROVIDER: S-EPMC12060445 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature